BAVUNALIMAB
UNII 3PT70X17VS

Substance Identification & Data

This profile provides standardized clinical and technical data for Bavunalimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 3PT70X17VS.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2329669-78-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

3PT70X17VS

CAS Registry Number

2329669-78-3

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

BAVUNALIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C159530

National Cancer Institute reference terminology for clinical and research data.

INN ID

11465

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

JK-27

Identifier assigned by the United States Adopted Names Council.

Substance Type

BAVUNALIMAB

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Bavunalimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

BAVUNALIMAB

Common Names & Synonyms

ANTI-CTLA-4/LAG-3 BISPECIFIC ANTIBODY XMAB22841

BAVUNALIMAB [USAN]

Bavunalimab [WHO-DD]

IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS LAG3 (LYMPHOCYTE ACTIVATING 3, LYMPHOCYTE-ACTIVATION 3, CD223)) AND ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)), MONOCLONAL ANTIBODY, BISPECIFIC; GAMMA1 HEAVY CHAIN ANTI-LAG3 (1-450) (VH (MUS MUSCULUS IGHV6-6*01 (88.0%)-(IGHD)-IGHJ1*01 (93.8%)/ HOMO SAPIENS IGHV3-72*01 (81.0%)-(IGHD)-IGHJ6*01 (86.0%)) CDR-IMGT (8.10.12) (26-33.51-60.99-110) (1-121)-HOMO SAPIENS IGHG1*03V, G1M3>G1M17, NG1M1 (CH1 N114>D (212) R120>K (218) (122-219), HINGE 1-15 (221-234), CH2 E1.4,L1.3>P (237), L1.2>V (238), G1.1>A (239), S29>K (270), Q84.2>E (298) (235-343), CH3 E12 (359), M14 (361), L24>D (375), K26>S (377), N44>D (387), Q97>E (421), N100>D (424), M107>L (431), N114>S (437) (344-448), CHS (449-450)) (122-450)), (224-218')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI-LAG3 (1'-218') (V-KAPPA (MUS MUSCULUS IGKV3-4*01 (82.8%)-(IGHD)-IGKJ4*01 (100%)/HOMO SAPIENS IGKV1-39*01 (82.8%)-IGKJ2*02 (90.9%)) CDR-IMGT (10.3.9) (27-36.54-56.93-101) (1'-111')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (157), V101 (195) (112'-218')); IG SCFV-H-CH2-CH3 SINGLE CHAIN, ANTI-CTLA4 (1''-477'') (SCFV VH-V-KAPPA ANTI-CTLA4 1''-246'') (VH (HOMO SAPIENS IGHV3-21*01 (91.8%)-(IGHD)-IGHJ3*01 (92.9%)) CDR-IMGT (8.8.11) (26-33.51-58.97-107) (1''-118'')-20-MER TETRAKIS(GLYCYL-LYSYL-PROLYL-GLYCYL-SERYL) LINKER (119''-138'')-V-KAPPA (HOMO SAPIENS IGKV3-20*01 (97.9%)-IGHJ1*01 (100%)) CDR-IMGT (7.3.9) (165-171.189-191.228-236) (139''-246''))-HOMO SAPIENS IGHG1*03 H-CH2-CH3, NG1M1 (247''-477'') (HINGE 1-15 C5>S (251) (247-261)-CH2 E1.4,L1.3>P (264), L1.2>V (265), G1.1>A (266), S29>K (297) (262-370),CH3 E12 (386), E13>Q (387), M14 (388), S20>K (394), M107>L (458), N114>S (464) (371-475), CHS (476-477))); DIMER (230-257'':233-260'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO)-S CELL LINE, GLYCOFORM ALFA

IMMUNOGLOBULIN, ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 SINGLE-CHAIN VARIABLE FRAGMENT VH-LINKER-VL) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C-REGION C-TERMINAL FRAGMENT), (257->230'),(260->233')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 ANTI-(HUMAN LYMPHOCYTE ACTIVATION GENE-3) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 .KAPPA.-CHAIN

PAVUNALIMAB

bavunalimab [INN]